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A B S T R A C T
Background
Formoterol has a fast onset of action and can therefore be used to relieve symptoms of asthma. A combination inhaler can deliver
formoterol with different doses of inhaled corticosteroid; when used as a reliever both drugs will be delivered more frequently when
asthma symptoms increase. This has the potential to treat both bronchoconstriction and inflammation in the early stages of exacerbations.
Objectives
To assess the efficacy and safety of combined inhalers containing both formoterol and an inhaled corticosteroid when used for reliever
therapy in adults and children with chronic asthma.
Search methods
We last searched the Cochrane Airways Group trials register in April 2009, and no new studies were found for inclusion in the review.
Selection criteria
Randomised trials in adults and children with chronic asthma, where a combination inhaler containing formoterol and inhaled
corticosteroid is compared with fast-acting beta2-agonist alone for the relief of asthma symptoms. This should be the only planned
difference between the trial arms.
Data collection and analysis
Two review authors independently extracted the characteristics and results of each study. Authors or manufacturers were asked to supply
unpublished data in relation to primary outcomes.
Main results
Three trials involving 5905 participants were included. In patients with mild asthma who do not need maintenance treatment, no
clinically important advantages of budesonide/formoterol as reliever were found in comparison to formoterol as reliever.
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Two studies enrolled patients with more severe asthma who were not controlled on high doses of inhaled corticosteroids (around 700
mcg/day in adults), and had suffered a clinically important asthma exacerbation in the past year. Hospitalisations related to asthma
in the two studies comparing budesonide/formoterol for maintenance and relief with the same dose of budesonide/formoterol for
maintenance with terbutaline for relief yielded an odds ratio of 0.68 (95% CI 0.40 to 1.16), which was not a statistically significant
reduction. In adults there was a reduction in exacerbations requiring oral corticosteroids compared to terbutaline, odds ratio 0.54 (95%
CI 0.44 to 0.65), which translates into a number needed to treat over 12 months of 15 (95% CI 13 to 21). The study in children
found less serious adverse events with budesonide/formoterol used for maintenance and relief. There was no significant difference in
annual growth in children using budesonide/formoterol reliever in comparison to terbutaline.
Authors’ conclusions
In mild asthma it is not yet known whether patients who use a budesonide/formoterol inhaler for relief of asthma symptoms derive any
clinically important benefits. In more severe asthma, two studies enrolled patients who were not controlled on inhaled corticosteroids,
and had suffered an exacerbation in the previous year, and then had their maintenance inhaled corticosteroids reduced in both arms
of the study. Under these conditions the studies demonstrated a reduction in the risk of exacerbations that require oral corticosteroids
with budesonide/formoterol for maintenance and relief in comparison with budesonide/formoterol for maintenance and terbutaline or
formoterol for relief. The incidence of serious adverse events in children was also less using budesonide/formoterol for maintenance and
relief in one study, which similarly enrolled children who were not controlled on inhaled corticosteroids, and who had their maintenance
inhaled corticosteroids reduced at the start of the study. This study also compared an explorative maintenance dose of budesonide/
formoterol that is not approved for treatment.
P L A I N L A N G U A G E S U M M A R Y
Formoterol and budesonide for the relief of asthma symptoms in adults and children
Combined formoterol and budesonide inhalers can be used for maintenance treatment of asthma and relief of symptoms. Three trials
involving 5905 participants were included. We found very little evidence in relation to the use of formoterol and budesonide for relief
of symptoms in people with mild asthma, but in people with more severe asthma who had suffered exacerbations in spite of regular
treatment with inhaled corticosteroids, we found that reliever formoterol and budesonide compared favourably with terbutaline in
reducing asthma exacerbations that required a course of oral corticosteroids. However only a small proportion of the ’severe asthma
exacerbations’ as defined in the trials led to hospital admissions, and no significant overall benefit has yet been shown for this outcome.
In children with asthma that was not controlled with regular inhaled corticosteroids, there were fewer serious adverse events when
formoterol and budesonide were used to relieve symptoms as well as for maintenance treatment.
B A C K G R O U N D
People with asthma take preventer therapy to maintain symptom
control, improve lung function and reduce the requirement for
emergency care. In response to symptoms, reliever medication in
the form of short-acting beta-agonists such as salbutamol or terbu-
taline, or formoterol (a long acting beta-agonist (LABA) with a fast
onset of action), can be used on an ’as needed’ basis (BTS 2003).
A maintenance combination therapy with formoterol in the com-
bination marketed as ’Symbicort’ combines preventer and reliever
therapy in a single inhaler, and allows both medications to be in-
creased simultaneouslywhen asthma symptoms increase (SMILE).
The pharmacological properties of salmeterol used in the Seretide/
Advair combination inhaler give bronchodilation with a slower
onset, and it is not licensed for use on an ’as needed’ basis. The
inclusion of inhaled corticosteroid (ICS) in a reliever inhaler for
use during episodes of loss of control requires monitoring for sa-
fety, efficacy and assessment of overall ICS dose.
Description of the intervention
In patients whose asthma remains poorly controlled on moderate
doses of inhaled corticosteroids (ICS), the addition of a LABA
has been shown to compare favourably with placebo (Ni Chroinin
2005) and increasing the dose of ICS (Greenstone 2005), and this
is a recommended approach in asthma guidelines (BTS 2003).
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There are concerns about the impact of LABA on exacerbation
rates in children (Bisgaard 2003). Traditionally patients have used
an additional short-acting beta2-agonist to relieve symptoms (on
top of their regular maintenance preventer treatment). Formoterol
is a long-acting beta2-agonist with fast onset of action (Palmqvist
2001). It is therefore also suitable for use in the relief of asthma
symptoms, and when taken as reliever therapy in combination
with ICS may have the added advantage of allowing the patient
to titrate their ICS treatment according to asthma symptoms.
How the intervention might work
The inflammatory component of chronic asthma can be reduced
by regular use of inhaled corticosteroids (Adams 2008), but many
patients default from treatment (Sovani 2008). Asthma exac-
erbations are preceded by many days of worsening symptoms
(Tattersfield 1999), but doubling inhaled corticosteroids has not
been shown to be effective in preventing exacerbations from de-
veloping (FitzGerald 2004; Harrison 2004). Deteriorating symp-
toms may be an early sign of an increase in underlying inflam-
mation, so including inhaled corticosteroids with formoterol in a
reliever inhaler is an alternative approach.
Why it is important to do this review
Concerns have been raised about the use of long-acting beta2-ag-
onists in chronic asthma, in particular when used without regular
inhaled corticosteroids, in relation to the possible increased risk of
severe adverse events such as intubation and asthma-related death
(Salpeter 2006; Walters 2007; Cates 2008; Cates 2008a). This
review is needed to identify and summarise the results of clinical
trials that compared budesonide/formoterol combination inhaler
as reliever therapy with other reliever inhalers.
O B J E C T I V E S
This review has been carried out to assess the efficacy and safety
of combined inhalers containing both formoterol and an inhaled
corticosteroid, when used for reliever therapy, in adults and chil-
dren with chronic asthma.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised trials of parallel group design were included in the
review.
Types of participants
Adults and children with a diagnosis of chronic asthma. We ac-
cepted trialist-defined asthma, recording the definition of asthma
used in the studies, and the entry criteria. We summarised base-
line severity of lung function and persistence of symptoms, and
we collected data on pre-study maintenance therapies. We did not
include studies conducted in an emergency department setting.
Types of interventions
Eligible treatment group intervention
This review included studies which assessed the effects of using
a combined formoterol and inhaled steroid delivered through a
single inhaler device for relief of symptoms. The intervention was
considered in three different drug therapy regimenswhichwe anal-
ysed separately:
1. As needed, in addition to regular maintenance therapy with
combination inhaled steroid and long-acting beta-agonist (i.e. as
needed and regular combination therapy).
2. As needed, in addition to regular maintenance therapy with
inhaled steroid only (i.e. as needed combination therapy and
regular ICS).
3. As needed only (i.e. combination therapy used without
maintenance treatment).
Eligible control group treatment
The control groups for the studies in this review consisted of a pre-
scribed fast-acting beta2-agonist such as terbutaline, salbutamol or
formoterol alone, given on an as needed basis. We plan to include
future studies which compare reliever therapy with combination
formoterol inhalers and other fast-acting beta2-agonists combined
in a single inhaler with an inhaled corticosteroid.
The maintenance dose of ICS or combination therapy had to be
the same in both treatment groups. Fixed dosing had to remain
stable within the control limbs of each of the studies. Study dura-
tion had to be greater than 12 weeks.
We did not consider studies that compared different combination
therapy inhalers (i.e. seretide versus symbicort), or titration of
maintenance dosing of combination therapy based on clinical signs
and symptoms.
Types of outcome measures
Primary outcomes
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1. Exacerbations of asthma requiring hospitalisation
2. Exacerbations of asthma requiring oral steroids
3. Serious adverse events (including mortality and life-
threatening events)
Secondary outcomes
1. Exacerbations (not otherwise specified)
2. Clinic spirometry Fixed Expiratory Volume in one second
(FEV1)
3. Diary card morning and evening peak expiratory flow (PEF)
4. Number of rescue medication puffs required per day
5. Symptoms
6. Quality of life
7. Adverse events
8. Study withdrawal
Search methods for identification of studies
Electronic searches
We identified trials using theCochrane Airways Group Specialised
Register of trials, which is derived from systematic searches of
bibliographic databases including the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL), MEDLINE, EMBASE,
CINAHL, AMED and PsycINFO, and handsearching of respira-
tory journals and meeting abstracts. All records in the Specialised
Register coded as ’asthma’ were searched using the following terms:
(“single inhaler therapy” or SiT or SMART or relie* or “as need*”
or as-need* or prn or flexible or titrat*) and ((combin* or symbi-
cort or viani) or ((steroid* or corticosteroid* or ICS or budesonide
or BUD or Pulmicort or beclomethasone or BDP or becotide)
and (“beta*agonist” or “beta*adrenergic agonist” or formoterol or
eformoterol or oxis or foradil)))
Searching other resources
We contacted trialists and manufacturers in order to confirm data
and to establish whether other unpublished or ongoing stud-
ies were available for assessment. We handsearched clinical tri-
als web sites (www.clinicalstudyresults.org; www.clinicaltrials.gov;
www.fda.gov) and the clinical trial web sites of manufacturers
(www.ctr.gsk.co.uk; www.astrazenecaclinicaltrials.com)
Data collection and analysis
Selection of studies
Following electronic literature searches, two review authors inde-
pendently selected articles on the basis of title or abstract or both
for full text scrutiny. The authors agreed a list of articles which
were retrieved, and they subsequently assessed each study to de-
termine whether it was a secondary publication of a primary study
publication, and to determine whether the study met the entry
criteria of the review.
Data extraction and management
We extracted information from each study for the following char-
acteristics:
Design (description of randomisation, blinding, number of study
centres and location, number of study withdrawals).
Participants (sample size (N), mean age, age range of the study,
baseline lung function, percentage on maintenance ICS or ICS/
LABA combination and average daily dose of steroid, entry crite-
ria).
Intervention (type and dose of component ICS and LABA, control
limb dosing schedule, inhaler device, study duration and run-in)
Outcomes (type of outcome analysis, outcomes analysed)
We extracted data for each of the outcomes considered by the
review from the trial publication(s) or from correspondence with
trialists or the manufacturer.
Assessment of risk of bias in included studies
We assessed trial bias protection in the following domains accord-
ing to whether studies meet the following pre-specified quality
criteria (as met, unmet or unclear, Handbook 2006):
1. Sequence Generation;
2. Allocation Concealment;
3. Blinding of participants and investigators;
4. Loss to follow up.
Assessment of heterogeneity
We measured statistical variation between combined studies by
the I-squared (I2) statistic (Higgins 2003).
Data synthesis
Data was combined with RevMan 5.0, using a fixed-effect mean
difference (calculated as either a weighted mean difference or a
mean difference weighted by generic inverse variance) for contin-
uous data variables, and a fixed-effect odds ratio for dichotomous
variables. For the primary outcome of exacerbations we planned
to calculate a number needed to treat to benefit (NNTB) for the
different levels of risk as represented by control group event rates
over a specified time period (www.nntonline.net).
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Subgroup analysis and investigation of heterogeneity
We looked at the data from adults and children separately. Adult
studies were considered as those which recruited participants from
18 upwards. Adult and adolescent studies were considered as those
which recruit participants from 12 upwards. We considered par-
ticipants in studies where the upper age limit was 12 years as chil-
dren, and in studies where the upper age limit was 18 years as
children and adolescents.
Sensitivity analysis
Sensitivity analysis was planned on the basis of risk of bias in
studies and methods of data analysis (fixed and random-effects
models).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The original search was out in April 2008 and included 199 ab-
stracts and a new search was also carried out in April 2009 which
included 30 further abstracts. Thirty six of the original abstracts
were potentially relevant and full text articles were obtained. There
were 11 citations relating to the three studies included in the re-
view and 25 citations for the 12 studies that were excluded (see
Characteristics of included studies and Characteristics of excluded
studies for full details).
The updated search did not yield any further studies for inclu-
sion; five potentially relevant full text articles were independently
assessed by CJC and TL. Stallberg 2008 was excluded because the
two comparison arms used differentmaintenance regimens (either
higher dose budesonide/formoterol or adjustable budesonide and
formoterol in separate inhalers). Two references were to existing
excluded studies (MONO and SALTO) and Riemersma 2008 was
excluded as the comparison was with usual care.
Included studies
The three trials (5905 participants) that are included in this review
have been considered as four separate data sources, in order to
separate the STAY study into children STAY - Children and adults
STAY - Adults. However it has not been possible to obtain separate
data for adults and children for all outcomes, so for these the
overall data has been entered under the label STAY - All ages.
SOMA
This was a small study on 92 adults with mild asthma who were
symptomatic but not taking any inhaled steroids, and had a con-
centration of nitric oxide in exhaled breath (FeNO) level of more
than 20 ppb. The mean pre-bronchodilator FEV1 was 101% pre-
dicted normal. Budesonide/formoterol 200/6 mcg was compared
with formoterol 6 mcg as reliever therapy (with no maintenance
therapy in either arm) over a 24 week treatment period. The pri-
mary outcome for this study was mean change in FeNO, but this
was not a pre-specified outcome for this review so the results are
not reported here.
SMILE
This was a large Multicentre study on 3394 adults and adolescents
with moderate to severe persistent asthma who had a history of
more than one severe asthma exacerbation in the past year, and
remained symptomatic on budesonide/formoterol 200/6 one in-
halation twice daily during a two week run-in. Their mean pre-
bronchodilator FEV1 was 72% predicted and the mean baseline
daily ICS level was 755mcg/day. Fifty nine per cent of participants
were also taking LABA before participating in the study. During
the 12 month trial period budesonide/formoterol 200/6 mcg one
inhalation twice daily was given as maintenance to all patients
(half the average dose of ICS used previously); the same inhaler as
reliever was compared to formoterol 6 mcg and terbutaline 500
mcg as reliever in the three arms of the study.
The definition of a severe asthma exacerbation in this study in-
cluded hospitalisation, emergency room (ER) visits or the need
for oral steroids for three days or more. The proportion of patients
with a severe exacerbation was the primary outcome used for the
power calculation in this study.
STAY - Adults
This was a large Multicentre study on 2419 adults and adolescents
with moderate to severe persistent asthma uncontrolled on ICS
(400 to 1000 mcg/day) and a history of at least one “clinically
important” exacerbation in the past year. Their mean pre-bron-
chodilator FEV1 was 73% predicted and the mean baseline daily
ICS level was 660 mcg/day. Twenty eight per cent of participants
(adults and children) were already taking LABA before participat-
ing in the study. To be eligible for randomisation patients had to
have used 12 or more inhalations of as-needed medication during
the last 10 days of run-in, when they were treated with their pre-
vious ICS but LABA was withdrawn. During the 12 month trial
period budesonide/formoterol 100/6 mcg one inhalation twice
daily was given as maintenance to all patients in two arms of the
study (one third of the previously prescribed dose of ICS); the
same inhaler as reliever was compared to terbutaline 500 mcg as
reliever. The third arm of the study did not contribute data to this
review as a higher dose of budesonide was used for maintenance
with terbutaline as reliever.
The definition of a severe asthma exacerbation in this study in-
cluded hospitalisation, emergency room (ER) visits, oral steroid
treatment, or morning peak flow of 70% or less of baseline on two
consecutive days. The primary efficacy variable was time to first
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severe asthma exacerbation.
STAY - Children
This was a subset of data presented from 341 children aged 4 to 11
years in the STAY study. They had moderate to severe persistent
asthma uncontrolled on ICS (200 to 500 mcg/day) and a history
of at least one “clinically important” exacerbation in the past year.
Their mean pre-bronchodilator FEV1 was 76% predicted and the
mean baseline daily ICS level was 315 mcg/day. The proportion
of children taking LABA before participating in the study is not
reported. To be eligible for randomisation patients had to have
used eight or more inhalations of as-neededmedication during the
last 10 days of run-in, when they were treated with their previous
ICS but LABA was withdrawn. During the 12 month trial period
budesonide/formoterol 100/6 mcg one inhalation in the evening
was given as maintenance to all patients in two arms of the study
(effectively one third of the previously prescribed dose of ICS);
the same inhaler as reliever was compared to terbutaline 500 mcg.
The third arm of the study did not contribute data to this review
as a higher dose of budesonide was used for maintenance with
terbutaline as reliever.
The definition of a severe asthma exacerbation in this study in-
cluded hospitalisation, emergency room (ER) visits, oral steroid
treatment, or morning peak flow of 70% or less of baseline on
two consecutive days. For children an increase in inhaled corticos-
teroids (via a separate inhaler), or other additional treatment were
also classified as severe asthma exacerbations. The primary efficacy
variable was time to first severe asthma exacerbation.
Excluded studies
Three of these studies (Ind 2002; Richter 2007; Tattersfield
2001) used formoterol alone as reliever therapy, and the other
studies (Bousquet 2007; COMPASS; COSMOS; Loukides
2005; Lundborg 2006; Scicchitano 2004; SOLO; Sovani 2008;
STEAM) were trials of Single Inhaler Therapy with budesonide/
formoterol but used different maintenance treatments as well as
comparing different reliever therapy.
Risk of bias in included studies
All the included studies had adequate sequence generation and
blinding, drop out rates were not high Figure 1. Although alloca-
tion concealment was not well-reported, it is likely that it was also
adequate in view of the sponsored nature of the studies.
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
Effects of interventions
Budesonide/formoterol as reliever in mild asthma
with no maintenance therapy
One small study in adults (SOMA) has looked at the effect of
reliever therapy with budesonide/formoterol 200/6 in comparison
with formoterol alone. All patients in the study had a baseline
FeNO of at least 20 ppb and this was the main outcome measure
for this study (but not a pre-specified outcome for this review).
No studies were found addressing this comparison in children.
Primary outcomes
There were no reported exacerbations requiring oral corticos-
teroids in this study and no reported hospitalisations. One patient
in the formoterol group took 12 reliever inhalations on one day,
and further information is awaited from the sponsors as to whether
this resulted in treatment with oral corticosteroids (as specified in
the trial protocol). Three serious adverse events were reported for
the budesonide/formoterol group (migraine, road traffic accident
and hydatidiformmolar pregnancy), compared to none in the for-
moterol group.
Secondary outcomes
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Reliever inhaler use rose in both groups from baseline levels of
3.9 inhalations/week to 5.7 inhalations per week for budesonide/
formoterol and from 3.2 to 5.9 inhalations/week for formoterol
alone. The proportion of rescue free days was 52% and 56% re-
spectively. These differences were not statistically significant.
There were no significant between group differences in morning
or evening PEF, asthma symptom scores or asthma free days. FEV1
increased from 102.4% to 104.2% predicted with budesonide/
formoterol, in comparison to a fall from99.5% to99.2%predicted
with formoterol. This represents a difference of 2.7% (0.7% to
4.7%), which is statistically significant but is of unproven clinical
importance.
Budesonide/formoterol as reliever in asthma with ICS
maintenance therapy
No trials were found (in adults or children) where ICS alone was
used as maintenance therapy at the same dose in both arms of
the trial, with budesonide/formoterol compared to beta2-agonist
alone as reliever.
Budesonide/formoterol as reliever in asthma with ICS
and LABA maintenance therapy compared to
terbutaline as reliever
Adults
Two studies contribute to this comparison (SMILE; STAY -Adults
). Both studies enrolled patients who were symptomatic on ICS
and had a history of previous exacerbations. The SMILE study
enrolled patients with a higher previous ICS intake (mean 755
mcg/day) and halved the ICS maintenance by using budesonide/
formoterol 200/6 mcg twice daily and compared the same inhaler
as reliever to formoterol and terbutaline. In contrast the patients
in STAY - Adults had a lower dose of previous ICS (mean 660
mcg/day) and this was reduced by two thirds by using a lower dose
of combined inhaler, budesonide/formoterol 100/6 mcg, as twice
daily maintenance and reliever compared to the samemaintenance
with terbutaline reliever. The patients in SMILE had to remain
symptomatic on budesonide/formoterol 200/6 mcg twice daily
during the run-in period, whereas those in STAY - Adults had to
be symptomatic on their previous ICS dosage without LABA.
Primary outcomes
The way that asthma exacerbations have been reported makes full
assessment of our primary outcomes impossible without further
information. A breakdown of the exacerbation data in both studies
has been requested from the sponsors; they have provided infor-
mation fromSTAY -Children in relation to the number of patients
who had a hospitalisation that was asthma related and additional
information from STAY - Adults on patients with one or more
courses of oral corticosteroids has now been added. As data on
serious adverse events that were asthma related is available from
SMILE, we have used this data as a proxy for asthma exacerbations
leading to hospital admission, (as almost all serious adverse events
are classified as serious due to admission to hospital).
No data was directly available from SMILE in relation to asthma
exacerbations leading to hospital admission. Moreover the pro-
portion of severe asthma exacerbations recorded that led to a hos-
pitalisation or ER visit is low in both studies; in SMILE one third
of exacerbations fall in this category and in STAY - All ages the
proportion is 13% of all severe exacerbations and 19% of those
severe exacerbations needing medical intervention. The only cur-
rent indication of the number of patients who were admitted to
hospital for asthma in SMILE comes from asthma-related serious
adverse events, of which there were 16 on budesonide/formoterol
and 26 on terbutaline . The sponsors have provided hospitalisa-
tion data from STAY - All ages and there were seven on budes-
onide/formoterol and eight on terbutaline. This is a close match
to the asthma-related serious adverse events, which yielded seven
adults on budesonide/formoterol and nine on terbutaline in this
category. The pooled results from both studies yield a combined
Odds Ratio of 0.68 (95% CI 0.40 to 1.16), Figure 2.
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Figure 2. Forest plot of comparison: 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance),
outcome: 1.1 Adults with an exacerbation causing hospitalisation.
Data onwith an asthma exacerbation requiring oral corticosteroids
was not originally reported for either study, but has been calculated
for SMILE (fromTable 2 in the paper publication), by subtracting
the number of patients with a hospitalisation or ER visit from the
total number that had a severe exacerbation.Therewas a significant
reduction in adults treated with oral corticosteroids in SMILE,
and data on this outcome has now been obtained from data on
file at AstraZeneca in relation to STAY - Adults. The combined
results from these two studies show a reduction in the number of
patients needing oral corticosteroids with single inhaler therapy,
Odds Ratio 0.54 (95% CI 0.44 to 0.65), Figure 3. This translates
into a number needed to treat over 12 months of 15 (95% CI
13 to 21) in order to prevent one patient being treated with oral
corticosteroids, Figure 4.
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Figure 3. Forest plot of comparison: 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance),
outcome: 1.2 Adults with an exacerbation treated with oral corticosteroids.
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Figure 4. In the control group 16 people out of 100 had asthma exacerbation needing oral steroids over 12
months, compared to 9 (95% CI 8 to 11) out of 100 for the active treatment group using single inhaler therapy
compared to terbutaline as reliever over 12 months. NNT(B) 15 (95% CI 13 to 21)
The combined data on adults with all cause serious adverse events
from STAY - Adults and SMILE did not show a significant differ-
ence between budesonide/formoterol and terbutaline as reliever,
Odds Ratio 1.04 (95% CI 0.79 to 1.36), Figure 5. There were
four deaths in 1,940 patients on terbutaline from the two studies
and one death in 1,914 patients on budesonide/formoterol, giv-
ing a pooled Odds Ratio of 0.34 (0.05 to 2.14) for all cause fatal
serious adverse events, Figure 6. There were no patients recorded
as having an asthma-related fatal event on budesonide/formoterol
and one patient on terbutaline, Figure 7.
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Figure 5. Forest plot of comparison: 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance),
outcome: 1.3 Adults with non-fatal Serious Adverse Events.
Figure 6. Forest plot of comparison: 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance),
outcome: 1.4 Adults with fatal serious adverse events.
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Figure 7. Forest plot of comparison: 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance),
outcome: 1.5 Adults with fatal serious adverse events related to asthma.
Secondary outcomes
The secondary outcomes were not reported separately for adults
in STAY - Adults, so as 87% of the total population were adults
and adolescents the combined data for all ages was used (STAY -
All ages). With the exception of asthma control days (where no
significant difference was seen), all the other secondary outcomes
favoured budesonide/formoterol as reliever, but the differences
were too small to be clinically significant. The pooled difference
in FEV1 for SMILE and STAY - All ages was 0.07 Litres (95% CI
0.05 to 0.09 Litres), Analysis 1.6, and morning peak flow showed
a pooled difference of 7.88 Litres/min (95% CI 5.11 to 10.66),
Analysis 1.7. The percentage of nights with awakenings fell from
20% in the run-in period to 9%onbudesonide/formoterol reliever
and 12% in fixed dose budesonide/formoterol with terbutaline
reliever in STAY - All ages. Overall the pooled risk difference was -
3.16% nights with awakenings (95% CI -4.64 to -1.69), Analysis
1.10.
Children
One study included 341 children aged from four to 11 years old
(STAY - Children). The childrenwere randomised into three treat-
ment arms, and for the purposes of this review those given budes-
onide/formoterol 100/6 mcg once daily (in the evening) with the
same inhaler to use for relief of symptoms were compared to the
same maintenance treatment with terbutaline for symptom relief.
The definition of severe exacerbations requiring medical interven-
tion in children was not the same as for adults in this study, but
also included an increase in ICS use (via a separate inhaler) and/
or additional treatment. Information has been requested from As-
traZeneca in order to assess children who had exacerbation by the
consequences; separate data on those who were admitted to hos-
pital, attended casualty or received a course of oral steroids are re-
quired to do this, for the primary outcome analysis in this review.
At present it has only been possible for AstraZeneca to provide
data on hospitalisation for asthma.
Primary outcomes
Data provided by AstraZeneca confirmed that there were hospi-
talisations related to asthma in seven patients on the fixed-dose
combination with terbutaline as reliever, but there were none in
patients using budesonide/formoterol as reliever, Figure 8. In ad-
dition one child given terbutaline as reliever had an asthma-re-
lated SAE that did not lead to hospitalisation. This reduction in
hospitalisation was large, Odds Ratio 0.06 (0.00 to 1.10) but the
confidence interval includes the possibility that this could have
arisen by chance (as the number of events was small).
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Figure 8. Forest plot of comparison: 2 BDF versus Terbutaline as reliever (Children with BDF
maintenance), outcome: 2.1 Children with an exacerbation causing hospitalisation.
The number of children with exacerbations requiring oral corti-
costeroids were not reported in the paper, although the number of
days on treatment was less with budesonide/formoterol as reliever
(32 versus 320 days, descriptive results only).
Childrenwith serious adverse events of any cause were significantly
less with budesonide/formoterol as reliever, (two events in contrast
to 16 events with fixed dose budesonide/formoterol and terbu-
taline as reliever, odds ratio 0.11 (95% CI 0.02 to 0.48), Figure
9. No fatal events were reported in children. It should also be
pointed out that the maintenance dose of budesonide/formoterol
used with terbutaline as reliever was only 100/6 mcg daily, which
the sponsors regard as an experimental dose and not approved for
treatment.
Figure 9. Forest plot of comparison: 2 BDF versus Terbutaline as reliever (Children with BDF
maintenance), outcome: 2.3 Children with non-fatal Serious Adverse Events.
Secondary outcomes
In contrast to the adults, the improvements seen in lung function
in this trial were not significant (Analysis 2.4; Analysis 2.5). The
use of relievers fell significantly more in the group using budes-
onide/formoterol as reliever, from an average of 1.6 inhalations
per day at baseline to 0.58 per day with budesonide/formoterol
and 0.76 per day in the terbutaline reliever group, a reduction of -
0.28 puffs per day (95% CI -0.54 to -0.02). Change in percentage
nights with awakenings is reported as a significant reduction in
the adjusted mean difference in favour of budesonide/formoterol.
However this represents 2.4% nights with awakenings on budes-
onide/formoterol and 4.4% on terbutaline, and the baseline dif-
ference between groups is the same size (12.8% and 10.8% re-
spectively), Analysis 2.7. Asthma control days (Analysis 2.8) and
annual growth (Analysis 2.9), did not show significant differences
between budesonide/formoterol and terbutaline.
Budesonide/formoterol as reliever in asthma with ICS
and LABA maintenance therapy compared to
formoterol as reliever
Only the SMILE study in adults contributed to this outcome, as
budesonide/formoterol as reliever was compared to formoterol in
one of the arms of this trial.
Primary outcomes
As there was no separate reporting of asthma exacerbations leading
to hospitalisation in the paper, we used serious adverse events
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relating to asthma as a measure of hospitalisation. There were 16
patients in the budesonide/formoterol arm in comparison to 23
in the formoterol arm, odds ratio 0.71 (95% CI 0.37 to 1.35),
Figure 10.
Figure 10. Forest plot of comparison: 3 BDF versus Formoterol as reliever (Adults with BDF maintenance),
outcome: 3.1 Adults with an exacerbation causing hospitalisation.
Asthma exacerbations requiring oral corticosteroids were not re-
ported but could be calculated by subtracting the number of pa-
tients with admissions/ER visits from the total number with ex-
acerbations. This represented a significant reduction using budes-
onide/formoterol as reliever from 120 to 89 patients, odds ratio
0.74 (95% CI 0.56 to 0.99), Figure 11 .
Figure 11. Forest plot of comparison: 3 BDF versus Formoterol as reliever (Adults with BDF maintenance),
outcome: 3.2 Adults with an exacerbation treated with oral corticosteroids.
Non-fatal serious adverse events relating from any cause were not
significantly different, budesonide/formoterol 70 participants and
formoterol 55 participants, odds ratio 1.33 (95%CI 0.92 to 1.91),
Figure 12. There were was one fatal serious adverse event on budes-
onide/formoterol and one on formoterol, neither was reported as
due to asthma.
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Figure 12. Forest plot of comparison: 3 BDF versus Formoterol as reliever (Adults with BDF maintenance),
outcome: 3.3 Adults with non-fatal Serious Adverse Events.
Secondary outcomes
The results for lung function, reliever use and night awakenings
were very similar to the findings when budesonide/formoterol
was compared to terbutaline, with clinically small, but statistically
significant advantages for budesonide/formoterol as reliever. See
Analysis 3.6 to Analysis 3.10. Again the difference in asthma con-
trol days was not statistically significant Analysis 3.11.
D I S C U S S I O N
Summary of main results
In patients with mild asthma who do not need maintenance
treatment, no clinically important advantages of budesonide/for-
moterol as reliever were found in comparison to formoterol as re-
liever.
In the two studies on patients with more severe asthma, who had
suffered a recent exacerbation in spite of quite high doses of in-
haled corticosteroids, a lower maintenance ICS dose (in the form
of regular budesonide/formoterol), and budesonide/formoterol as
reliever was compared to formoterol or terbutaline as reliever.Hos-
pital admissions make up a small proportion of those reported
as having a severe asthma exacerbation, and the combined results
yield a non-significant pooled odds ratio of 0.68 (95% CI 0.40
to 1.16). The use of oral corticosteroids was significantly lower
in SMILE (both in comparison to formoterol or terbutaline as
reliever), but comparative data from STAY - All ages are not cur-
rently available. Serious adverse events were not significantly dif-
ferent in adults, but in children there were significantly less seri-
ous adverse events in the group using budesonide/formoterol as
maintenance and reliever, in comparison to those on budesonide/
formoterol maintenance and terbutaline as reliever. However the
maintenance dose of budesonide/formoterol used with terbutaline
as reliever was only 100/6 mcg daily, which the sponsors regard as
an experimental dose and not approved for treatment.
There was no significant difference in annual growth in children
using budesonide/formoterol reliever in comparison to terbutaline
in STAY - Children.
Overall completeness and applicability of
evidence
The application of the results of SMILE, STAY - Adults and STAY
- Children should be in the light of the patients enrolled in these
trials, who all had suffered an asthma exacerbation in the past
year, were not controlled on quite high doses of inhaled corti-
costeroids, and then were all treated with a lower dose of main-
tenance inhaled corticosteroid treatment. Data for our primary
outcome were rarely available in a format usable for meta-analy-
sis as dichotomous data, nor were exacerbation types sub-divided
sufficiently to give a complete overview of exacerbations from the
studies we included. There remains some uncertainty as to how
complete our numerical analyses are.
Quality of the evidence
All the included studies were double blind. Although allocation
concealment was not clearly reported, we concluded that the in-
cluded studies were unlikely to have suffered from selection bias,
as they were carried out by the sponsors for regulatory purposes.
Potential biases in the review process
Reporting of serious adverse events was not uniform across the
studies, and the use of a composite outcome for exacerbations with
no separate reporting of hospital admissions for asthma makes the
possibility of publication bias a concern. A report on the manu-
facturer’s controlled trial web site was only found for STAY - All
ages and STAY - Children.
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Agreements and disagreements with other
studies or reviews
The use of budesonide/formoterol as a reliever therapy for asthma
is subject to product license, and this is currently restricted; for
example use as reliever is restricted to adults over 18 years in the
British National Formulary (issue 55).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In mild asthma it is not yet known whether patients who use a
budesonide/formoterol inhaler for relief of asthma symptoms de-
rive any clinically important benefits. In more severe asthma, two
studies enrolled patients who were not controlled on inhaled cor-
ticosteroids, and had suffered an exacerbation in the previous year,
and then had their maintenance inhaled corticosteroids reduced
in both arms of the study. Under these conditions the studies
demonstrated a reduction in the risk of exacerbations that require
oral corticosteroids with budesonide/formoterol for maintenance
and relief in comparison with budesonide/formoterol for mainte-
nance and terbutaline or formoterol for relief. The incidence of
serious adverse events in children was also less using budesonide/
formoterol for maintenance and relief in one study, which simi-
larly enrolled children who were not controlled on inhaled corti-
costeroids, and who had theirmaintenance inhaled corticosteroids
reduced at the start of the study. This study also compared an ex-
plorative maintenance dose of budesonide/formoterol that is not
approved for treatment.
Implications for research
More research is needed in the use of budesonide/formoterol for
symptom relief in patients with less severe asthma, particularly
in those patients who take low doses of inhaled corticosteroids.
Asthma exacerbations reporting should include patients with hos-
pital admissions and those treated with oral corticosteroids, the
composite of these outcomes, and transparent reporting of serious
adverse events.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
SMILE
Methods Study Design: Randomised, double-blind, parallel group study over a 12 month period
in 289 centres in 20 countries (between April 2003 and Dec 2004)
Participants Population: 3394 asthmatic adults aged 12 years or more with asthma previously on
ICS and symptomatic on budesonide/formoterol 200/6 twice daily during 2 week run-
in, with more than one exacerbation in the past year. The maintenance treatment was
budesonide/formoterol for all patients and terbutaline, formoterol and budesonide/for-
moterol were compared as reliever therapy
Adults Mean age: 42 years. FEV1 72% predicted pre bronchodilator. Mean ICS dose
at enrolment 755 mcg/day. Hospital admission for asthma in the past year: unknown
proportion. Course of oral steroids for asthma in past year: unknown proportion
Inclusion Criteria: Outpatients aged 12+ years, clinical diagnosis of asthma with ICS
for at least 3 months, and steady dose for at least 4 weeks. More than one severe asthma
exacerbation in the past 12 months was required. Prebronchodilator FEV1 of 50-100%
predicted normal value and at least 12% reversibility following Terbutaline. To be in-
cluded patients had to need at rescue inhalations for 5 or more of the last 7 days of run-
in. Adults using ten or more rescue inhalations in a single day or with oral steroid course
during previous 4 weeks were not included
Interventions 1. Budesonide/formoterol 200/6 mcg twice daily [400 mcg budesonide/day], and
as needed (one maintenance and one relief Turbuhaler)
2. Budesonide/formoterol 200/6 mcg twice daily [400 mcg budesonide/day], and
Formoterol 6 mcg as needed (one maintenance and one relief Turbuhaler)
3. Budesonide/formoterol 200/6 mcg twice daily [400 mcg budesonide/day], and
Terbutaline 500 mcg as needed (one maintenance and one relief Turbuhaler)
Maximum of 10 as needed inhalations could be used per day before contacting the
investigator
Outcomes Primary outcome - time to first severe exacerbations. Secondary outcomes included
number of severe exacerbations, number of days with hospitalisation, ER room visit or
both, and days of oral steroid use were recorded
Exacerbation Definition: Severe - Deterioration in asthma requiring hospital or emer-
gency room treatment, or oral steroids (for 3 days or more). Severe exacerbations did
not include change in PEF . Mild exacerbation day - defined as PEF 80% or less of
baseline this was the average of 10 days before randomisation, relief medication 2 or
more inhalations above baseline, (not awakenings due to asthma). Mild exacerbation
defined as 2 consecutive mild exacerbation days using the same criteria
Notes SAE data given (70,55,65) of these (16,23,26) were related to asthma. Deaths given for
whole trial (1,1,2)
Funding source - AstraZeneca.
Risk of bias
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SMILE (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated by an independent
person
Allocation concealment? Unclear At each centre, eligible patients were se-
quentially assigned a randomisation code
by the investigator from the computer-gen-
erated list
Blinding?
All outcomes
Yes Double blind. All as-needed study medica-
tion was given by identical turbuhalers
Incomplete outcome data addressed?
All outcomes
Yes Withdrawals and Dropouts: 2989/3374
(88%) completed the study
SOMA
Methods Study Design: Randomised, double-blind, parallel group study over 24 weeks. In the
14 days of run-in patients had to use a reliever on one to five of the last ten days to be
eligible
Participants Population: 92 asthmatic adults with intermittent mild asthma needing a maximum of
two doses of reliever medication per week in the preceding months, with FeNO of at
least 20 ppb at enrolment or randomisation. There was no maintenance treatment and
formoterol and budesonide/formoterol were compared as reliever therapy
Adults Mean age: 36 years. FEV1 101% predicted pre bronchodilator. Mean ICS dose
at enrolment zero mcg/day.
Inclusion Criteria: Outpatients aged 15+ years, clinical diagnosis of asthma with no ICS
for at least 3 months, and no regular maintenance treatment. Prebronchodilator FEV1
of over 80% predicted normal value and at least 12% reversibility following terbutaline
or salbutamol, or documented fall in FEV1 of at least 12% after exercise. PEF had to
demonstrate at least 15% variability in 2 or more days over 2 weeks, or 15% rise post
bronchodilator. To be included patients had to need rescue inhalations for 1 to 5 of the
last 10 days of run-in.
Interventions 1. Budesonide/formoterol 200/6 mcg twice as reliever (one Turbuhaler). No main-
tenance therapy
2. Formoterol 6 mcg as reliever (one Turbuhaler). No maintenance therapy
Maximum of 12 as needed inhalations could be used per day before contacting the
investigator. Patients taking maximum reliever were treated with oral prednisolone and
removed from the study if more asthma medication was needed
Outcomes Primary outcome - mean change in FeNO. Secondary outcomes included asthma symp-
tom scores, asthma-free days, PEF, FEV1 and number of inhalations of study drug. No
mention is made with regard to courses of oral prednisolone in each group
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SOMA (Continued)
Notes SAE data given (0,3), none of these were related to asthma.
Funding source - AstraZeneca.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation at each study centre was
performed in balanced blocks using a com-
puter programme
Allocation concealment? Unclear no details
Blinding?
All outcomes
Yes Double blind
Incomplete outcome data addressed?
All outcomes
Yes 77/93 (83%) completed the study
STAY - Adults
Methods Study Design: Randomised, double-blind, parallel group study over a 12 month period
in 246 centres in 22 countries (between Jan 2001 and Jan 2003). In the 14-18 day run-
in patients used pre-study ICS with terbutaline for symptom relief (LABA had to be
discontinued at least 3 days before run-in)
Participants Adult Population: 2419 asthmatic adults aged 12 years or more with asthma uncon-
trolled on ICS (400-1000 mcg/day) and a history of at least one “clinically important”
exacerbation in the past year. The maintenance ICS dose was cut to about one third with
additional Budesonide/formoterol (SiT) compared to terbutaline for relief
Adults Mean age: 40 years. FEV1 73% predicted pre bronchodilator. Mean ICS dose
at enrolment 660 mcg/day. Hospital admission for asthma in the past year: unknown
proportion. Course of oral steroids for asthma in past year: unknown proportion
Inclusion Criteria: Aged 12-80 years, with a constant dose of ICS (400-1000 mcg/day)
at least 3 months. Prebronchodilator FEV1 of 60-90% predicted normal value and at
least 12% reversibility following Terbutaline. To be included patients had to need at
least 12 rescue inhalations in the last 10 days of run-in. Adults using ten or more rescue
inhalations in a single day or with an exacerbation during run-in were not randomised
Interventions 1. Budesonide/formoterol 100/6 mcg twice daily [200 mcg budesonide/day] and
as needed (one maintenance and one relief Turbuhaler)
2. Budesonide/formoterol 100/6 mcg twice daily [200 mcg budesonide/day] and
Terbutaline as needed (one maintenance and one relief Turbuhaler)
3. Budesonide 400 mcg twice daily [800 mcg budesonide/day] and Terbutaline as
needed (one maintenance and one relief Turbuhaler)
Maximum of 10 as needed inhalations could be used per day before contacting the
investigator
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STAY - Adults (Continued)
Outcomes Primary outcome - time to first severe exacerbations. Secondary outcomes included
number of severe exacerbations, time to mild exacerbations, number of mild exacerba-
tions, symptom free days, QOL scores. No particular variable was chosen to assess safety
Exacerbation Definition: Severe - Deterioration in asthma requiring hospital or emer-
gency room treatment, or oral steroids (or other additional treatment) or morning PEF
70% or less of baseline on two consecutive days. Severe exacerbations requiring med-
ical intervention were analysed separately . Mild exacerbation day - PEF 80% or less
of baseline, relief medication 2 or more inhalations above baseline, or awakenings due
to asthma. Mild exacerbation defined as 2 consecutive mild exacerbation days using the
same criteria
Notes SAE data (44,46,42) in the adult population; deaths given for whole trial (0,2,1)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated randomisation
scheme
Allocation concealment? Unclear Eligible patients were randomised in bal-
anced blocks by allocating patient numbers
in consecutive order
Blinding?
All outcomes
Yes Double blind. All study medication was
given by turbuhalers. Maintenance and as
needed medication distinguished by the
colour of the label and its wording
Incomplete outcome data addressed?
All outcomes
Yes Withdrawals and Dropouts: 2039/2419
(84%) completed the study
STAY - All ages
Methods see STAY - Adults and STAY - children
Participants Combined data on Children and Adults aged 4 to 60 years with a history of one or more
exacerbations in the past year
Interventions see STAY - Adults and STAY - children
Outcomes see STAY - Adults and STAY - children
Notes Data presented for adults and children. P values based on ANOVA and changes from
baseline calculated from Tables 1 and 2 in the primary publication. Standard Errors
estimated from P values
Risk of bias
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STAY - All ages (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Yes see STAY - Adults and STAY - children
Allocation concealment? Unclear see STAY - Adults and STAY - children
Blinding?
All outcomes
Yes see STAY - Adults and STAY - children
Incomplete outcome data addressed?
All outcomes
Yes see STAY - Adults & STAY - children
STAY - Children
Methods Study Design: Randomised, double-blind, parallel group study over a 12 month period
in 41 centres in 12 countries (between Jan 2001 and Jan 2003). In the 14-18 day run-
in patients used pre-study ICS with terbutaline for symptom relief (LABA had to be
discontinued at least 3 days before run-in)
Participants Children in Study: 341 asthmatic children aged 4-11 years with asthma uncontrolled on
ICS (200-500 mcg/day) and a history of at least one “clinically important” exacerbation
in the past year
Mean age: 8 years. Mean morning PEF: 220 L/min. FEV1 76% predicted pre bron-
chodilator. Mean ICS dose at enrolment 315 mcg/day. Hospital admission for asthma
in the past year: unknown proportion. Course of oral steroids for asthma in past year:
unknown proportion
Inclusion Criteria: Aged 4-11 years, with a constant dose of ICS (200-500 mcg/day) at
least 3months. Prebronchodilator FEV1 of 60-100% predicted normal value and at least
12% reversibility following Terbutaline. To be included patients had to need at least 8
rescue inhalations in the last 10 days of run-in. Children using seven or more rescue
inhalations in a single day or with an exacerbation during run-in were not randomised
Interventions 1. Budesonide 100 mcg (80 mcg delivered dose) and Formoterol 4.5 mcg in the
evening and as needed (one maintenance and one relief Turbuhaler)
2. Budesonide 100 mcg (80 mcg delivered dose) and Formoterol 4.5 mcg in the
evening and Terbutaline as needed (one maintenance and one relief Turbuhaler)
3. Budesonide 400 mcg (320 mcg delivered dose) in the evening and Terbutaline
as needed (one maintenance and one relief Turbuhaler)
Outcomes Primary outcome - time to first severe exacerbations. Secondary outcomes included
number of severe exacerbations, time to mild exacerbations, number of mild exacerba-
tions, symptom free days, QOL scores. No particular variable was chosen to assess safety
Exacerbation Definition: Severe - Deterioration in asthma requiring hospital or emer-
gency room treatment, or oral steroids (or an increase in ICS or other additional
treatment) or morning PEF 70% or less of baseline on two consecutive days. Severe
exacerbations requiring medical intervention were analysed separately . Mild exac-
erbation day - PEF 80% or less of baseline, relief medication 2 or more inhalations above
baseline, or awakenings due to asthma. Mild exacerbation defined as 2 consecutive mild
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STAY - Children (Continued)
exacerbation days using the same criteria
Notes Adverse Events:SAE data given (2,16,5) of these (0,7,2) were related to asthma. Change
from baseline nights with awakenings were the same in both groups, P value in the paper
not used as it related to post treatment levels not changes. No SD data published in
the paper with respect to growth comparing budesonide/formoterol to Terbutaline as
reliever, so SD calculated from the other comparisons presented
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated randomisation
scheme
Allocation concealment? Unclear Eligible patients were randomised in bal-
anced blocks by allocating patient numbers
in consecutive order
Blinding?
All outcomes
Yes Double blind. All study medication was
given by turbuhalers. Maintenance and as
needed medication distinguished by the
colour of the label and its wording
Incomplete outcome data addressed?
All outcomes
Yes 309/341 (91%) completed the study
FEV1: Forced expiratory volume in one second
ICS: Inhaled corticosteroids
LABA: Long acting beta-agonist
PEF: Peak expiratory flow
SAE: Serious Adverse Event
SD: Standard deviation
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Balanzat 2004 Overview of three existing trials
Bousquet 2007 Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone
COMPASS Different doses of Symbicort used for maintenance
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(Continued)
COSMOS Different maintenance regimen in each arm
D5890C00003 SiT compared to higher dose maintenance regimen
Ind 2002 Formoterol v Terbutaline as reliever
Jenkins 2007 budesonide/formoterol dose adjustment with FeNO (not used as reliever)
Jonkers 2006 Single dose study
Loukides 2005 Maintenance with symbicort 200/6 mcg bd in SiT group and Budesonide 200 mcg with Formoterol 12 mg bd
with formoterol reliever
Lundborg 2006 Higher dose maintenance therapy in the arm using formoterol as reliever
MONO SiT compared to conventional best treatment
NCT00235911 Comparison of SiT with usual care
NCT00252863 SiT compared to current best practice
Richter 2007 Formoterol not combination therapy as reliever
Riemersma 2008 SiT compared to usual care
SALTO SiT compared to conventional best practice
Scicchitano 2004 SiT compared to higher dose budesonide
SOLO SiT compared to conventional best practice (different maintenance regimen)
Sovani 2008 SiT compared to budesonide (different maintenance regimen)
Stallberg 2008 SiT compared to adjustablemaintenance separate budesonide and formoterol inhalers or higher dose combination
budesonide/formoterol inhaler
STEAM SiT compared to higher dose maintenance therapy
STYLE SiT compared to conventional best practice
Tattersfield 2001 Formoterol versus Terbutaline as reliever
bd: twice daily
FeNO:- exhaled nitric oxide
SiT: Single inhaler therapy
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D A T A A N D A N A L Y S E S
Comparison 1. BDF versus Terbutaline as reliever (Adults with BDF maintenance)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adults with an exacerbation
causing hospitalisation
2 3837 Odds Ratio (M-H, Fixed, 95% CI) 0.68 [0.40, 1.16]
1.1 High dose BDF (200/6)
maintenance and relief
1 2245 Odds Ratio (M-H, Fixed, 95% CI) 0.63 [0.33, 1.18]
1.2 Lower dose BDF (100/6)
maintenance and relief
1 1592 Odds Ratio (M-H, Fixed, 95% CI) 0.86 [0.31, 2.37]
2 Adults with an exacerbation
treated with oral corticosteroids
2 3838 Odds Ratio (M-H, Fixed, 95% CI) 0.54 [0.44, 0.65]
2.1 High dose BDF (200/6)
maintenance and relief
1 2245 Odds Ratio (M-H, Fixed, 95% CI) 0.56 [0.42, 0.74]
2.2 Lower dose BDF (100/6)
maintenance and relief
1 1593 Odds Ratio (M-H, Fixed, 95% CI) 0.51 [0.38, 0.68]
3 Adults with non-fatal Serious
Adverse Events
2 3854 Odds Ratio (M-H, Fixed, 95% CI) 1.04 [0.80, 1.37]
3.1 High dose BDF (200/6)
maintenance and relief
1 2245 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.79, 1.58]
3.2 Lower dose BDF (100/6)
maintenance and relief
1 1609 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.62, 1.45]
4 Adults with fatal serious adverse
events
2 3854 Odds Ratio (M-H, Fixed, 95% CI) 0.34 [0.05, 2.14]
4.1 High dose BDF (200/6)
maintenance and relief
1 2245 Odds Ratio (M-H, Fixed, 95% CI) 0.51 [0.05, 5.67]
4.2 Lower dose BDF (100/6)
maintenance and relief
1 1609 Odds Ratio (M-H, Fixed, 95% CI) 0.20 [0.01, 4.14]
5 Adults with fatal serious adverse
events related to asthma
2 3854 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.13]
5.1 High dose BDF (200/6)
maintenance and relief
1 2245 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
5.2 Lower dose BDF (100/6)
maintenance and relief
1 1609 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.13]
6 FEV1 (Change from baseline)
Litres
2 3844 Mean Difference (Fixed, 95% CI) 0.07 [0.05, 0.09]
6.1 High dose BDF (200/6)
maintenance and relief
1 2245 Mean Difference (Fixed, 95% CI) 0.08 [0.05, 0.11]
6.2 Low dose BDF (100/6)
maintenance and relief
1 1599 Mean Difference (Fixed, 95% CI) 0.05 [0.02, 0.08]
7 Morning Peak Flow (Change
from baseline) L/min
2 3844 Mean Difference (Fixed, 95% CI) 7.88 [5.11, 10.66]
7.1 High dose BDF (200/6)
maintenance and relief
1 2245 Mean Difference (Fixed, 95% CI) 7.5 [4.28, 10.72]
7.2 Low dose BDF (100/6)
maintenance and relief
1 1599 Mean Difference (Fixed, 95% CI) 9.0 [3.51, 14.49]
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8 Evening Peak Flow (Change
from baseline) L/min
2 3844 Mean Difference (Fixed, 95% CI) 7.17 [4.31, 10.03]
8.1 High dose BDF (200/6)
maintenance and relief
1 2245 Mean Difference (Fixed, 95% CI) 6.30 [3.13, 9.47]
8.2 Low dose BDF (100/6)
maintenance and relief
1 1599 Mean Difference (Fixed, 95% CI) 11.0 [4.34, 17.66]
9 Change in reliever use (puffs per
24 hours)
2 4079 Mean Difference (Fixed, 95% CI) -0.21 [-0.28, -0.14]
9.1 High dose BDF (200/6)
maintenance and relief
1 2245 Mean Difference (Fixed, 95% CI) -0.2 [-0.28, -0.12]
9.2 Low dose BDF (100/6)
maintenance and relief
1 1834 Mean Difference (Fixed, 95% CI) -0.24 [-0.39, -0.09]
10 Change in % nights with
awakenings
2 4079 Mean Difference (Fixed, 95% CI) -3.16 [-4.64, -1.69]
10.1 High dose BDF (200/6)
maintenance and relief
1 2245 Mean Difference (Fixed, 95% CI) -2.6 [-4.28, -0.92]
10.2 Low dose BDF (100/6)
maintenance and relief
1 1834 Mean Difference (Fixed, 95% CI) -5.0 [-8.04, -1.96]
11 Change in % Asthma Control
Days
2 4079 Mean Difference (Fixed, 95% CI) 1.91 [-0.58, 4.40]
11.1 High dose BDF (200/6)
maintenance and relief
1 2245 Mean Difference (Fixed, 95% CI) 1.9 [-0.72, 4.52]
11.2 Low dose BDF (100/6)
maintenance and relief
1 1834 Mean Difference (Fixed, 95% CI) 2.0 [-5.84, 9.84]
Comparison 2. BDF versus Terbutaline as reliever (Children with BDF maintenance)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Children with an exacerbation
causing hospitalisation
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Children with non-fatal Serious
Adverse Events
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3 FEV1 (Change from baseline)
Litres
1 Mean Difference (Fixed, 95% CI) Totals not selected
4 Morning Peak Flow (Change
from baseline) L/min
1 Mean Difference (Fixed, 95% CI) Totals not selected
5 Evening Peak Flow (Change
from baseline) L/min
1 Mean Difference (Fixed, 95% CI) Totals not selected
6 Change in reliever use (puffs per
24 hours)
1 Mean Difference (Fixed, 95% CI) Totals not selected
7 Change in % nights with
awakenings
1 Mean Difference (Fixed, 95% CI) Totals not selected
8 Change in % Asthma Control
Days
1 Mean Difference (Fixed, 95% CI) Totals not selected
9 Annual Height Gain (cms) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
30Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 3. BDF versus Formoterol as reliever (Adults with BDF maintenance)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adults with an exacerbation
causing hospitalisation
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 High dose BDF (200/6)
maintenance and relief
1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
2 Adults with an exacerbation
treated with oral corticosteroids
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 High dose BDF (200/6)
maintenance and relief
1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
3 Adults with non-fatal Serious
Adverse Events
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 High dose BDF (200/6)
maintenance and relief
1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
4 Adults with fatal serious adverse
events
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 High dose BDF (200/6)
maintenance and relief
1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
5 Adults with fatal serious adverse
events related to asthma
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 High dose BDF (200/6)
maintenance and relief
1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
6 FEV1 (Change from baseline)
Litres
1 Mean Difference (Fixed, 95% CI) Totals not selected
6.1 High dose BDF (200/6)
maintenance and relief
1 Mean Difference (Fixed, 95% CI) Not estimable
7 Morning Peak Flow (Change
from baseline) L/min
1 Mean Difference (Fixed, 95% CI) Totals not selected
7.1 High dose BDF (200/6)
maintenance and relief
1 Mean Difference (Fixed, 95% CI) Not estimable
8 Evening Peak Flow (Change
from baseline) L/min
1 Mean Difference (Fixed, 95% CI) Totals not selected
8.1 High dose BDF (200/6)
maintenance and relief
1 Mean Difference (Fixed, 95% CI) Not estimable
9 Change in reliever use (puffs per
24 hours)
1 Mean Difference (Fixed, 95% CI) Totals not selected
9.1 High dose BDF (200/6)
maintenance and relief
1 Mean Difference (Fixed, 95% CI) Not estimable
10 Change in nights with
awakenings (%)
1 Mean Difference (Fixed, 95% CI) Totals not selected
10.1 High dose BDF (200/6)
maintenance and relief
1 Mean Difference (Fixed, 95% CI) Not estimable
11 Change in Asthma Control
Days (%)
1 Mean Difference (Fixed, 95% CI) Totals not selected
11.1 High dose BDF (200/6)
maintenance and relief
1 Mean Difference (Fixed, 95% CI) Not estimable
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Analysis 1.1. Comparison 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance), Outcome 1
Adults with an exacerbation causing hospitalisation.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance)
Outcome: 1 Adults with an exacerbation causing hospitalisation
Study or subgroup BDF Terbutaline Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 High dose BDF (200/6) maintenance and relief
SMILE 16/1107 26/1138 75.9 % 0.63 [ 0.33, 1.18 ]
Subtotal (95% CI) 1107 1138 75.9 % 0.63 [ 0.33, 1.18 ]
Total events: 16 (BDF), 26 (Terbutaline)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
2 Lower dose BDF (100/6) maintenance and relief
STAY - Adults 7/804 8/788 24.1 % 0.86 [ 0.31, 2.37 ]
Subtotal (95% CI) 804 788 24.1 % 0.86 [ 0.31, 2.37 ]
Total events: 7 (BDF), 8 (Terbutaline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.77)
Total (95% CI) 1911 1926 100.0 % 0.68 [ 0.40, 1.16 ]
Total events: 23 (BDF), 34 (Terbutaline)
Heterogeneity: Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
0.01 0.1 1 10 100
Favours BDF Favours terbutaline
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Analysis 1.2. Comparison 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance), Outcome 2
Adults with an exacerbation treated with oral corticosteroids.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance)
Outcome: 2 Adults with an exacerbation treated with oral corticosteroids
Study or subgroup BDF Terbutaline Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 High dose BDF (200/6) maintenance and relief
SMILE 89/1107 154/1138 51.6 % 0.56 [ 0.42, 0.74 ]
Subtotal (95% CI) 1107 1138 51.6 % 0.56 [ 0.42, 0.74 ]
Total events: 89 (BDF), 154 (Terbutaline)
Heterogeneity: not applicable
Test for overall effect: Z = 4.15 (P = 0.000034)
2 Lower dose BDF (100/6) maintenance and relief
STAY - Adults 83/804 145/789 48.4 % 0.51 [ 0.38, 0.68 ]
Subtotal (95% CI) 804 789 48.4 % 0.51 [ 0.38, 0.68 ]
Total events: 83 (BDF), 145 (Terbutaline)
Heterogeneity: not applicable
Test for overall effect: Z = 4.53 (P < 0.00001)
Total (95% CI) 1911 1927 100.0 % 0.54 [ 0.44, 0.65 ]
Total events: 172 (BDF), 299 (Terbutaline)
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 6.13 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 0.0), I2 =0.0%
0.5 0.7 1 1.5 2
Favours BDF Favours terbutaline
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Analysis 1.3. Comparison 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance), Outcome 3
Adults with non-fatal Serious Adverse Events.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance)
Outcome: 3 Adults with non-fatal Serious Adverse Events
Study or subgroup BDF Terbutaline Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 High dose BDF (200/6) maintenance and relief
SMILE 70/1107 65/1138 57.9 % 1.11 [ 0.79, 1.58 ]
Subtotal (95% CI) 1107 1138 57.9 % 1.11 [ 0.79, 1.58 ]
Total events: 70 (BDF), 65 (Terbutaline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
2 Lower dose BDF (100/6) maintenance and relief
STAY - Adults 44/807 46/802 42.1 % 0.95 [ 0.62, 1.45 ]
Subtotal (95% CI) 807 802 42.1 % 0.95 [ 0.62, 1.45 ]
Total events: 44 (BDF), 46 (Terbutaline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
Total (95% CI) 1914 1940 100.0 % 1.04 [ 0.80, 1.37 ]
Total events: 114 (BDF), 111 (Terbutaline)
Heterogeneity: Chi2 = 0.33, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.75)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 0.0), I2 =0.0%
0.01 0.1 1 10 100
Favours BDF Favours terbutaline
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Analysis 1.4. Comparison 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance), Outcome 4
Adults with fatal serious adverse events.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance)
Outcome: 4 Adults with fatal serious adverse events
Study or subgroup BDF Terbutaline Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 High dose BDF (200/6) maintenance and relief
SMILE 1/1107 2/1138 44.0 % 0.51 [ 0.05, 5.67 ]
Subtotal (95% CI) 1107 1138 44.0 % 0.51 [ 0.05, 5.67 ]
Total events: 1 (BDF), 2 (Terbutaline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
2 Lower dose BDF (100/6) maintenance and relief
STAY - Adults 0/807 2/802 56.0 % 0.20 [ 0.01, 4.14 ]
Subtotal (95% CI) 807 802 56.0 % 0.20 [ 0.01, 4.14 ]
Total events: 0 (BDF), 2 (Terbutaline)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Total (95% CI) 1914 1940 100.0 % 0.34 [ 0.05, 2.14 ]
Total events: 1 (BDF), 4 (Terbutaline)
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
0.005 0.1 1 10 200
Favours BDF Favours terbutaline
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Analysis 1.5. Comparison 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance), Outcome 5
Adults with fatal serious adverse events related to asthma.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance)
Outcome: 5 Adults with fatal serious adverse events related to asthma
Study or subgroup BDF Terbutaline Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 High dose BDF (200/6) maintenance and relief
SMILE 0/1107 0/1138 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 1107 1138 0.0 [ 0.0, 0.0 ]
Total events: 0 (BDF), 0 (Terbutaline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
2 Lower dose BDF (100/6) maintenance and relief
STAY - Adults 0/807 1/802 0.33 [ 0.01, 8.13 ]
Subtotal (95% CI) 807 802 0.33 [ 0.01, 8.13 ]
Total events: 0 (BDF), 1 (Terbutaline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Total (95% CI) 1914 1940 0.33 [ 0.01, 8.13 ]
Total events: 0 (BDF), 1 (Terbutaline)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
0.01 0.1 1 10 100
Favours BDF Favours terbutaline
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Analysis 1.6. Comparison 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance), Outcome 6
FEV1 (Change from baseline) Litres.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance)
Outcome: 6 FEV1 (Change from baseline) Litres
Study or subgroup BDF Terbutaline Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 High dose BDF (200/6) maintenance and relief
SMILE 1107 1138 0.08 (0.013) 58.1 % 0.08 [ 0.05, 0.11 ]
Subtotal (95% CI) 58.1 % 0.08 [ 0.05, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.15 (P < 0.00001)
2 Low dose BDF (100/6) maintenance and relief
STAY - All ages 807 792 0.05 (0.0153) 41.9 % 0.05 [ 0.02, 0.08 ]
Subtotal (95% CI) 41.9 % 0.05 [ 0.02, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.27 (P = 0.0011)
Total (95% CI) 100.0 % 0.07 [ 0.05, 0.09 ]
Heterogeneity: Chi2 = 2.23, df = 1 (P = 0.14); I2 =55%
Test for overall effect: Z = 6.81 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.23, df = 1 (P = 0.14), I2 =55%
-0.2 -0.1 0 0.1 0.2
Favours terbutaline Favours BDF
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Analysis 1.7. Comparison 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance), Outcome 7
Morning Peak Flow (Change from baseline) L/min.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance)
Outcome: 7 Morning Peak Flow (Change from baseline) L/min
Study or subgroup BDF Terbutaline Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 High dose BDF (200/6) maintenance and relief
SMILE 1107 1138 7.5 (1.642) 74.4 % 7.50 [ 4.28, 10.72 ]
Subtotal (95% CI) 74.4 % 7.50 [ 4.28, 10.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.57 (P < 0.00001)
2 Low dose BDF (100/6) maintenance and relief
STAY - All ages 807 792 9 (2.8) 25.6 % 9.00 [ 3.51, 14.49 ]
Subtotal (95% CI) 25.6 % 9.00 [ 3.51, 14.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.21 (P = 0.0013)
Total (95% CI) 100.0 % 7.88 [ 5.11, 10.66 ]
Heterogeneity: Chi2 = 0.21, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 5.57 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.21, df = 1 (P = 0.64), I2 =0.0%
-10 -5 0 5 10
Favours terbutaline Favours BDF
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Analysis 1.8. Comparison 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance), Outcome 8
Evening Peak Flow (Change from baseline) L/min.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance)
Outcome: 8 Evening Peak Flow (Change from baseline) L/min
Study or subgroup BDF Terbutaline Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 High dose BDF (200/6) maintenance and relief
SMILE 1107 1138 6.3 (1.616) 81.6 % 6.30 [ 3.13, 9.47 ]
Subtotal (95% CI) 81.6 % 6.30 [ 3.13, 9.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.90 (P = 0.000097)
2 Low dose BDF (100/6) maintenance and relief
STAY - All ages 807 792 11 (3.4) 18.4 % 11.00 [ 4.34, 17.66 ]
Subtotal (95% CI) 18.4 % 11.00 [ 4.34, 17.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.24 (P = 0.0012)
Total (95% CI) 100.0 % 7.17 [ 4.31, 10.03 ]
Heterogeneity: Chi2 = 1.56, df = 1 (P = 0.21); I2 =36%
Test for overall effect: Z = 4.91 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.56, df = 1 (P = 0.21), I2 =36%
-50 -25 0 25 50
Favours terbutaline Favours BDF
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Analysis 1.9. Comparison 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance), Outcome 9
Change in reliever use (puffs per 24 hours).
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance)
Outcome: 9 Change in reliever use (puffs per 24 hours)
Study or subgroup BDF Terbutaline Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 High dose BDF (200/6) maintenance and relief
SMILE 1107 1138 -0.2 (0.0429) 75.3 % -0.20 [ -0.28, -0.12 ]
Subtotal (95% CI) 75.3 % -0.20 [ -0.28, -0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.66 (P < 0.00001)
2 Low dose BDF (100/6) maintenance and relief
STAY - All ages 925 909 -0.24 (0.075) 24.7 % -0.24 [ -0.39, -0.09 ]
Subtotal (95% CI) 24.7 % -0.24 [ -0.39, -0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.20 (P = 0.0014)
Total (95% CI) 100.0 % -0.21 [ -0.28, -0.14 ]
Heterogeneity: Chi2 = 0.21, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 5.64 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.21, df = 1 (P = 0.64), I2 =0.0%
-1 -0.5 0 0.5 1
Favours BDF Favours terbutaline
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Analysis 1.10. Comparison 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance), Outcome
10 Change in % nights with awakenings.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance)
Outcome: 10 Change in % nights with awakenings
Study or subgroup BDF Terbutaline Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 High dose BDF (200/6) maintenance and relief
SMILE 1107 1138 -2.6 (0.859) 76.5 % -2.60 [ -4.28, -0.92 ]
Subtotal (95% CI) 76.5 % -2.60 [ -4.28, -0.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.03 (P = 0.0025)
2 Low dose BDF (100/6) maintenance and relief
STAY - All ages 925 909 -5 (1.55) 23.5 % -5.00 [ -8.04, -1.96 ]
Subtotal (95% CI) 23.5 % -5.00 [ -8.04, -1.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.23 (P = 0.0013)
Total (95% CI) 100.0 % -3.16 [ -4.64, -1.69 ]
Heterogeneity: Chi2 = 1.83, df = 1 (P = 0.18); I2 =45%
Test for overall effect: Z = 4.21 (P = 0.000025)
Test for subgroup differences: Chi2 = 1.83, df = 1 (P = 0.18), I2 =45%
-10 -5 0 5 10
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Analysis 1.11. Comparison 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance), Outcome
11 Change in % Asthma Control Days.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 1 BDF versus Terbutaline as reliever (Adults with BDF maintenance)
Outcome: 11 Change in % Asthma Control Days
Study or subgroup BDF Terbutaline Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 High dose BDF (200/6) maintenance and relief
SMILE 1107 1138 1.9 (1.338) 89.9 % 1.90 [ -0.72, 4.52 ]
Subtotal (95% CI) 89.9 % 1.90 [ -0.72, 4.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
2 Low dose BDF (100/6) maintenance and relief
STAY - All ages 925 909 2 (4) 10.1 % 2.00 [ -5.84, 9.84 ]
Subtotal (95% CI) 10.1 % 2.00 [ -5.84, 9.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
Total (95% CI) 100.0 % 1.91 [ -0.58, 4.40 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
-20 -10 0 10 20
Favours terbutaline Favours BDF
Analysis 2.1. Comparison 2 BDF versus Terbutaline as reliever (Children with BDF maintenance), Outcome
1 Children with an exacerbation causing hospitalisation.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 2 BDF versus Terbutaline as reliever (Children with BDF maintenance)
Outcome: 1 Children with an exacerbation causing hospitalisation
Study or subgroup BDF (100/6) Terbutaline Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
STAY - Children 0/118 7/117 0.06 [ 0.00, 1.10 ]
0.005 0.1 1 10 200
Favours BDF Favours terbutaline
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Analysis 2.2. Comparison 2 BDF versus Terbutaline as reliever (Children with BDF maintenance), Outcome
2 Children with non-fatal Serious Adverse Events.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 2 BDF versus Terbutaline as reliever (Children with BDF maintenance)
Outcome: 2 Children with non-fatal Serious Adverse Events
Study or subgroup BDF (100/6) Terbutaline Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
STAY - Children 2/118 16/117 0.11 [ 0.02, 0.48 ]
0.01 0.1 1 10 100
Favours BDF Favours terbutaline
Analysis 2.3. Comparison 2 BDF versus Terbutaline as reliever (Children with BDF maintenance), Outcome
3 FEV1 (Change from baseline) Litres.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 2 BDF versus Terbutaline as reliever (Children with BDF maintenance)
Outcome: 3 FEV1 (Change from baseline) Litres
Study or subgroup BDF Terbutaline Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
STAY - Children 118 117 0.06 (0.035) 0.06 [ -0.01, 0.13 ]
-0.5 -0.25 0 0.25 0.5
Favours terbutaline Favours BDF
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Analysis 2.4. Comparison 2 BDF versus Terbutaline as reliever (Children with BDF maintenance), Outcome
4 Morning Peak Flow (Change from baseline) L/min.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 2 BDF versus Terbutaline as reliever (Children with BDF maintenance)
Outcome: 4 Morning Peak Flow (Change from baseline) L/min
Study or subgroup BDF Terbutaline Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
STAY - Children 118 117 3 (2.45) 3.00 [ -1.80, 7.80 ]
-10 -5 0 5 10
Favours terbutaline Favours BDF
Analysis 2.5. Comparison 2 BDF versus Terbutaline as reliever (Children with BDF maintenance), Outcome
5 Evening Peak Flow (Change from baseline) L/min.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 2 BDF versus Terbutaline as reliever (Children with BDF maintenance)
Outcome: 5 Evening Peak Flow (Change from baseline) L/min
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
STAY - Children 3 (2.25) 3.00 [ -1.41, 7.41 ]
-10 -5 0 5 10
Favours terbutaline Favours BDF
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Analysis 2.6. Comparison 2 BDF versus Terbutaline as reliever (Children with BDF maintenance), Outcome
6 Change in reliever use (puffs per 24 hours).
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 2 BDF versus Terbutaline as reliever (Children with BDF maintenance)
Outcome: 6 Change in reliever use (puffs per 24 hours)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
STAY - Children -0.28 (0.135) -0.28 [ -0.54, -0.02 ]
-0.5 -0.25 0 0.25 0.5
Favours BDF Favours terbutaline
Analysis 2.7. Comparison 2 BDF versus Terbutaline as reliever (Children with BDF maintenance), Outcome
7 Change in % nights with awakenings.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 2 BDF versus Terbutaline as reliever (Children with BDF maintenance)
Outcome: 7 Change in % nights with awakenings
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
STAY - Children -2 (0.7) -2.00 [ -3.37, -0.63 ]
-4 -2 0 2 4
Favours terbutaline Favours BDF
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Analysis 2.8. Comparison 2 BDF versus Terbutaline as reliever (Children with BDF maintenance), Outcome
8 Change in % Asthma Control Days.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 2 BDF versus Terbutaline as reliever (Children with BDF maintenance)
Outcome: 8 Change in % Asthma Control Days
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
STAY - Children -2.1 (4) -2.10 [ -9.94, 5.74 ]
-10 -5 0 5 10
Favours terbutaline Favours BDF
Analysis 2.9. Comparison 2 BDF versus Terbutaline as reliever (Children with BDF maintenance), Outcome
9 Annual Height Gain (cms).
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 2 BDF versus Terbutaline as reliever (Children with BDF maintenance)
Outcome: 9 Annual Height Gain (cms)
Study or subgroup BDF Terbutaline
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
STAY - Children 118 5.3 (2.7) 117 5.4 (2.7) -0.10 [ -0.79, 0.59 ]
-1 -0.5 0 0.5 1
Favours experimental Favours control
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Analysis 3.1. Comparison 3 BDF versus Formoterol as reliever (Adults with BDF maintenance), Outcome 1
Adults with an exacerbation causing hospitalisation.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 3 BDF versus Formoterol as reliever (Adults with BDF maintenance)
Outcome: 1 Adults with an exacerbation causing hospitalisation
Study or subgroup BDF Formoterol Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 High dose BDF (200/6) maintenance and relief
SMILE 16/1107 23/1137 0.71 [ 0.37, 1.35 ]
0.01 0.1 1 10 100
Favours BDF Favours Formoterol
Analysis 3.2. Comparison 3 BDF versus Formoterol as reliever (Adults with BDF maintenance), Outcome 2
Adults with an exacerbation treated with oral corticosteroids.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 3 BDF versus Formoterol as reliever (Adults with BDF maintenance)
Outcome: 2 Adults with an exacerbation treated with oral corticosteroids
Study or subgroup BDF Formoterol Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 High dose BDF (200/6) maintenance and relief
SMILE 89/1107 120/1137 0.74 [ 0.56, 0.99 ]
0.5 0.7 1 1.5 2
Favours BDF Favours Formoterol
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Analysis 3.3. Comparison 3 BDF versus Formoterol as reliever (Adults with BDF maintenance), Outcome 3
Adults with non-fatal Serious Adverse Events.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 3 BDF versus Formoterol as reliever (Adults with BDF maintenance)
Outcome: 3 Adults with non-fatal Serious Adverse Events
Study or subgroup BDF Formoterol Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 High dose BDF (200/6) maintenance and relief
SMILE 70/1107 55/1137 1.33 [ 0.92, 1.91 ]
0.5 0.7 1 1.5 2
Favours BDF Favours Formoterol
Analysis 3.4. Comparison 3 BDF versus Formoterol as reliever (Adults with BDF maintenance), Outcome 4
Adults with fatal serious adverse events.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 3 BDF versus Formoterol as reliever (Adults with BDF maintenance)
Outcome: 4 Adults with fatal serious adverse events
Study or subgroup BDF Terbutaline Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 High dose BDF (200/6) maintenance and relief
SMILE 1/1107 1/1138 1.03 [ 0.06, 16.46 ]
0.01 0.1 1 10 100
Favours BDF Favours terbutaline
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Analysis 3.5. Comparison 3 BDF versus Formoterol as reliever (Adults with BDF maintenance), Outcome 5
Adults with fatal serious adverse events related to asthma.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 3 BDF versus Formoterol as reliever (Adults with BDF maintenance)
Outcome: 5 Adults with fatal serious adverse events related to asthma
Study or subgroup BDF Terbutaline Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 High dose BDF (200/6) maintenance and relief
SMILE 0/1107 0/1138 0.0 [ 0.0, 0.0 ]
0.01 0.1 1 10 100
Favours BDF Favours terbutaline
Analysis 3.6. Comparison 3 BDF versus Formoterol as reliever (Adults with BDF maintenance), Outcome 6
FEV1 (Change from baseline) Litres.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 3 BDF versus Formoterol as reliever (Adults with BDF maintenance)
Outcome: 6 FEV1 (Change from baseline) Litres
Study or subgroup BDF Formoterol Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 High dose BDF (200/6) maintenance and relief
SMILE 1107 1137 0.05 (0.015) 0.05 [ 0.02, 0.08 ]
-0.1 -0.05 0 0.05 0.1
Favours Formoterol Favours BDF
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Analysis 3.7. Comparison 3 BDF versus Formoterol as reliever (Adults with BDF maintenance), Outcome 7
Morning Peak Flow (Change from baseline) L/min.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 3 BDF versus Formoterol as reliever (Adults with BDF maintenance)
Outcome: 7 Morning Peak Flow (Change from baseline) L/min
Study or subgroup BDF Formoterol Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 High dose BDF (200/6) maintenance and relief
SMILE 1107 1137 4.8 (1.641) 4.80 [ 1.58, 8.02 ]
-10 -5 0 5 10
Favours Formoterol Favours BDF
Analysis 3.8. Comparison 3 BDF versus Formoterol as reliever (Adults with BDF maintenance), Outcome 8
Evening Peak Flow (Change from baseline) L/min.
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 3 BDF versus Formoterol as reliever (Adults with BDF maintenance)
Outcome: 8 Evening Peak Flow (Change from baseline) L/min
Study or subgroup BDF Formoterol Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 High dose BDF (200/6) maintenance and relief
SMILE 1107 1137 5.4 (1.641) 5.40 [ 2.18, 8.62 ]
-10 -5 0 5 10
Favours Formoterol Favours BDF
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Analysis 3.9. Comparison 3 BDF versus Formoterol as reliever (Adults with BDF maintenance), Outcome 9
Change in reliever use (puffs per 24 hours).
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 3 BDF versus Formoterol as reliever (Adults with BDF maintenance)
Outcome: 9 Change in reliever use (puffs per 24 hours)
Study or subgroup BDF Formoterol Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 High dose BDF (200/6) maintenance and relief
SMILE 1107 1137 -0.17 (0.0429) -0.17 [ -0.25, -0.09 ]
-0.2 -0.1 0 0.1 0.2
Favours BDF Favours Formoterol
Analysis 3.10. Comparison 3 BDF versus Formoterol as reliever (Adults with BDF maintenance), Outcome
10 Change in nights with awakenings (%).
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 3 BDF versus Formoterol as reliever (Adults with BDF maintenance)
Outcome: 10 Change in nights with awakenings (%)
Study or subgroup BDF Formoterol Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 High dose BDF (200/6) maintenance and relief
SMILE 1107 1137 -2 (0.833) -2.00 [ -3.63, -0.37 ]
-4 -2 0 2 4
Favours BDF Favours Formoterol
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Analysis 3.11. Comparison 3 BDF versus Formoterol as reliever (Adults with BDF maintenance), Outcome
11 Change in Asthma Control Days (%).
Review: Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Comparison: 3 BDF versus Formoterol as reliever (Adults with BDF maintenance)
Outcome: 11 Change in Asthma Control Days (%)
Study or subgroup BDF Formoterol Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 High dose BDF (200/6) maintenance and relief
SMILE 1107 1137 2.4 (1.364) 2.40 [ -0.27, 5.07 ]
-4 -2 0 2 4
Favours terbutaline Favours BDF
F E E D B A C K
Study generalisability and interpretational issues, 9 March 2009
Summary
1. The patients recruited to the studies were randomised to receive lower doses of ICS than they had been taking prior to study
entry, and would do poorly compared to those that received reliever/ICS. The control groups in both the SMILE and STAY studies
are essentially set up to fail. In our opinion, this critical point about the inappropriate treatment given to the control group (although
briefly mentioned in the review) was not emphasized enough.
2. The SMILE and STAY studies are really attempting to see if using ICS for relief is worthwhile as both treatment arms get reliever
medications; the only difference is that one group receives ICS and the other does not.
3. Did the authors confirm that patients who were hospitalized did not receive oral steroids as well? Did the authors confirm that
exacerbations were counted properly? If a patient was first hospitalized for an exacerbation, and then later had another exacerbation
not requiring hospitalization (a subsequent event), was the latter counted and reported? And if so was this accounted for in the
current review?
4. The authors state that selection bias was unlikely as trials were all double-blinded. As we understand it, double-blinding limits
reporting/assessment/concomitant treatment bias and it is allocation concealment procedures that limit selection bias. With regard to
implications for research we do not feel that use of a combination reliever in patients with less severe asthma would be of clinical
value. If patients only require low dose ICS or no ICS then why expose them to the potential for adverse events of corticosteroids even
if it is through intermittent use?
5. The serious adverse event findings did not receive enough emphasis. The suggestion that severe asthmatics derived a benefit from
reliever/ICS would only be true if serious adverse events rates were lower for this group compared to the formoterol alone patients. In
other words, the reduction in exacerbations requiring oral steroids should have correlated with a reduction in serious adverse events, if
the combination produces a net benefit, but it did not. A more appropriate conclusion would have been that no overall health benefit
was proven in adults with severe asthma despite the potential reduction in exacerbations requiring steroids.
52Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Reply
We address these comments on a point by point basis as follows:
1. We agree that the study populations recruited were randomised to receive a lower dose of steroid than they had previously been
treated with. We have stated this more clearly in the abstract and conclusions of the review, although we have not restated this in the
discussion since we feel that this is clearly emphasized already.
2. The corticosteroid is co-delivered with formoterol and compared with terbutaline in most of the studies we included. It is true
that both groups of participants receive reliever medications, but essentially the studies are assessing the combination of ICS with a
long-acting beta-agonist with a fast onset against a short-acting beta-agonist alone.
3. This point refers to the first published version of the review. Since the review was published, we have received data on OCS-
treated exacerbations from the sponsors of the studies and analysed these data as per protocol. The data provided by the sponsors
enabled us to add these findings as binary data for both OCS-treated exacerbations and hospital admission in December 2008 (see
History of review in the What’s new section). The results have been presented as patients with at least one hospital admission or
course of oral steroids (as described in the protocol for the review); this is to avoid unit of analysis errors which can arise when
multiple events in a single patient are counted as if they came from separate patients.
4. We have clarified that our judgement of selection bias is based on sequence generation and allocation concealment (not on
double blinding).
5. We have made the SAE data in the review available for users to make up their own minds about the benefits and risks of
treatment. We disagree that we should conclude overall benefit in favour of combination therapy only when SAEs favour this form of
therapy. Our primary outcomes included oral steroid use, which favoured combination therapy, and SAEs which did not indicate that
either form of relief therapy had an advantage over the other.
We thank Dr Tejani for these comments.
Contributors
Aaron Tejani & Vivian Yih
WH A T ’ S N E W
Last assessed as up-to-date: 20 April 2008.
Date Event Description
15 July 2009 Amended Correction to contributors who made the comment posted in March 2009
H I S T O R Y
Protocol first published: Issue 2, 2008
Review first published: Issue 1, 2009
Date Event Description
21 April 2009 New search has been performed New search carried out in April 2009 but no new stud-
ies found for inclusion
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(Continued)
9 March 2009 Feedback has been incorporated Comment submitted relating to study generalisability
and interpretational issues. Changes made to emphasis
on some of the results, and rebuttal included in the
review
11 December 2008 Amended Additional data incorporated in relation to patients
with at least one course of oral corticosteroids in STAY
- Adults. The conclusions are unchanged as the results
are very similar to the same outcome from SMILE that
were already included in the review.
14 March 2008 Amended Converted to new review format.
14 December 2007 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
CJC: Conception of the idea, study selection and data collection, statistical analysis, and co-writing of the review.
TL: Discussion of concepts, study selection and data collection and co-writing of the review.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• NHS R&D, UK.
External sources
• No sources of support supplied
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The review authors have included studies with no maintenance therapy, (but not combined the results with other studies of patients
on maintenance ICS). Formoterol with ICS is the focus of this review, so salmeterol has been removed from the search terms, as it is
not used for reliever therapy. The primary outcome has been modified to patients with exacerbations (rather than rates) that require
hospitalisation or courses of oral steroids. All-cause serious adverse events (fatal and non-fatal) have been added as a further primary
outcome.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Inhalation; Adolescent; Anti-Asthmatic Agents [∗administration & dosage]; Asthma [∗drug therapy]; Bronchial Dis-
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